120 related articles for article (PubMed ID: 2688721)
1. Pharmacodynamics of FUT-175 anticoagulant in adsorbent plasma perfusion.
Yamazaki Z; Hiraishi M; Kanai F; Takahama T; Idezuki Y; Inoue N
ASAIO Trans; 1989; 35(3):567-9. PubMed ID: 2688721
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis].
Pak K; Shirasu A; Okino K; Sako H; Nakane Y; Umemura K; Maeda S; Tomoyoshi T
Hinyokika Kiyo; 1988 Jun; 34(6):1077-81. PubMed ID: 3223453
[TBL] [Abstract][Full Text] [Related]
3. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
Akizawa T
Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168
[TBL] [Abstract][Full Text] [Related]
4. Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant.
Hiraishi M; Yamazaki Z; Ichikawa K; Kanai F; Idezuki Y; Onishi K; Takahama T; Inoue N
Int J Artif Organs; 1988 May; 11(3):212-6. PubMed ID: 3403059
[TBL] [Abstract][Full Text] [Related]
5. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report.
Nagaya M; Futamura M; Kato J; Niimi N; Fukuta S
J Pediatr Surg; 1997 Apr; 32(4):531-5. PubMed ID: 9126748
[TBL] [Abstract][Full Text] [Related]
6. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding.
Akizawa T; Koshikawa S; Ota K; Kazama M; Mimura N; Hirasawa Y
Nephron; 1993; 64(3):376-81. PubMed ID: 8341382
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
Tsukagoshi S
Gan To Kagaku Ryoho; 2000 May; 27(5):767-74. PubMed ID: 10832450
[TBL] [Abstract][Full Text] [Related]
8. Nafamostat mesilate administration during cardiopulmonary bypass decreases postoperative bleeding after cardiac surgery.
Sato T; Tanaka K; Kondo C; Morimoto T; Yada I; Yuasa H; Kusagawa M; Deguchi K
ASAIO Trans; 1991; 37(3):M194-5. PubMed ID: 1751106
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
Matsuo T; Kario K; Nakao K; Yamada T; Matsuo M
Haemostasis; 1993; 23(3):135-41. PubMed ID: 8276316
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of nafamstat mesilate (FUT 175). A new anticoagulant for plasmapheresis.
Hosokawa S; Oyamaguchi A; Yoshida O
ASAIO J; 1992; 38(1):59-60. PubMed ID: 1554918
[TBL] [Abstract][Full Text] [Related]
11. Adsorption of nafamostat mesilate by hemodialysis membranes.
Inagaki O; Nishian Y; Iwaki R; Nakagawa K; Takamitsu Y; Fujita Y
Artif Organs; 1992 Dec; 16(6):553-8. PubMed ID: 1482323
[TBL] [Abstract][Full Text] [Related]
12. Comparative clinical trial of regional anticoagulation for hemodialysis.
Akizawa T; Kitaoka T; Sato M; Koshikawa S; Hirasawa Y; Kazama M; Mimura N; Ota K
ASAIO Trans; 1988; 34(3):176-8. PubMed ID: 3058171
[TBL] [Abstract][Full Text] [Related]
13. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs.
Minamiguchi K; Kitazato KT; Sasaki E; Nagase H; Kitazato K
Thromb Haemost; 1997 Jun; 77(6):1148-53. PubMed ID: 9241748
[TBL] [Abstract][Full Text] [Related]
14. [Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit].
Takano H; Miyamoto Y; Kaneko M; Matsuwaka R; Kuratani T; Amemiya A; Nakano S; Matsuda H
Nihon Kyobu Geka Gakkai Zasshi; 1993 Nov; 41(11):2166-73. PubMed ID: 8283086
[TBL] [Abstract][Full Text] [Related]
15. Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery.
Tanaka K; Kondo C; Takagi K; Sato T; Yada I; Yuasa H; Kusagawa M
ASAIO J; 1993; 39(3):M545-9. PubMed ID: 8268595
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of nafamostat mesilate as a regional anticoagulant in experimental direct hemoperfusion and in plasma exchange on humans.
Abe H; Tani T; Numa K; Endo Y; Yoshioka T; Kodama M
Artif Organs; 1992 Apr; 16(2):206-8. PubMed ID: 10078246
[TBL] [Abstract][Full Text] [Related]
17. Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model.
Minamiguchi K; Kitazato KT; Nagase H; Sasaki E; Ohwada K; Kitazato K
Kidney Int; 2003 Apr; 63(4):1548-55. PubMed ID: 12631372
[TBL] [Abstract][Full Text] [Related]
18. [The effects of FUT-175 (nafamostat mesilate) on blood coagulation and experimental disseminated intravascular coagulation (DIC)].
Koshiyama Y; Kobori A; Ogihara M; Yokomoto Y; Ohtani K; Shimamura K; Iwaki M
Nihon Yakurigaku Zasshi; 1987 Dec; 90(6):313-20. PubMed ID: 3443413
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological studies of FUT-175, nafamstat mesilate. IV. Effects on coagulation, platelets and fibrinolysis].
Koshiyama Y; Ozeki M; Motoyoshi A; Fujita M; Iwaki M; Aoyama T
Nihon Yakurigaku Zasshi; 1984 Nov; 84(5):417-28. PubMed ID: 6519580
[TBL] [Abstract][Full Text] [Related]
20. Ideal anticoagulation for use with a left ventricular assist device.
Takahama T; Kanai F; Onishi K; Yamazaki Z; Furuse A; Yoshitake T
ASAIO J; 1995; 41(3):M779-82. PubMed ID: 8573913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]